JP2014514324A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014514324A5 JP2014514324A5 JP2014506618A JP2014506618A JP2014514324A5 JP 2014514324 A5 JP2014514324 A5 JP 2014514324A5 JP 2014506618 A JP2014506618 A JP 2014506618A JP 2014506618 A JP2014506618 A JP 2014506618A JP 2014514324 A5 JP2014514324 A5 JP 2014514324A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- reagent
- antibody
- sequence
- identity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003153 chemical reaction reagent Substances 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 39
- 238000006467 substitution reaction Methods 0.000 claims description 16
- 239000000427 antigen Substances 0.000 claims description 15
- 102000036639 antigens Human genes 0.000 claims description 15
- 108091007433 antigens Proteins 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 13
- 239000012636 effector Substances 0.000 claims description 10
- 102000012002 Aquaporin 4 Human genes 0.000 claims description 9
- 108010036280 Aquaporin 4 Proteins 0.000 claims description 9
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 8
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 238000001228 spectrum Methods 0.000 claims description 6
- 208000016192 Demyelinating disease Diseases 0.000 claims description 4
- 206010012305 Demyelination Diseases 0.000 claims description 4
- 230000034994 death Effects 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 230000009251 neurologic dysfunction Effects 0.000 claims description 3
- 208000015015 neurological dysfunction Diseases 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 206010028813 Nausea Diseases 0.000 claims description 2
- 208000003435 Optic Neuritis Diseases 0.000 claims description 2
- 206010047700 Vomiting Diseases 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 210000001130 astrocyte Anatomy 0.000 claims description 2
- 230000030833 cell death Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000005713 exacerbation Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 238000001361 intraarterial administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 230000008693 nausea Effects 0.000 claims description 2
- 210000004248 oligodendroglia Anatomy 0.000 claims description 2
- 210000001328 optic nerve Anatomy 0.000 claims description 2
- 230000002035 prolonged effect Effects 0.000 claims description 2
- 210000003994 retinal ganglion cell Anatomy 0.000 claims description 2
- 210000000278 spinal cord Anatomy 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 208000009174 transverse myelitis Diseases 0.000 claims description 2
- 230000008673 vomiting Effects 0.000 claims description 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 208000030768 Optic nerve injury Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161477955P | 2011-04-21 | 2011-04-21 | |
| US61/477,955 | 2011-04-21 | ||
| PCT/US2012/034662 WO2012145746A1 (en) | 2011-04-21 | 2012-04-23 | Compositions and methods for the treatment of neuromyelitis optica |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014514324A JP2014514324A (ja) | 2014-06-19 |
| JP2014514324A5 true JP2014514324A5 (https=) | 2015-06-18 |
| JP6152090B2 JP6152090B2 (ja) | 2017-06-21 |
Family
ID=47041960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014506618A Expired - Fee Related JP6152090B2 (ja) | 2011-04-21 | 2012-04-23 | 視神経脊髄炎を処置するための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10654916B2 (https=) |
| EP (1) | EP2699256B1 (https=) |
| JP (1) | JP6152090B2 (https=) |
| KR (1) | KR20140059168A (https=) |
| CN (1) | CN103702682A (https=) |
| AU (1) | AU2012245205B2 (https=) |
| CA (1) | CA2833785C (https=) |
| WO (1) | WO2012145746A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011075185A1 (en) | 2009-12-18 | 2011-06-23 | Oligasis | Targeted drug phosphorylcholine polymer conjugates |
| JP6152090B2 (ja) | 2011-04-21 | 2017-06-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ | 視神経脊髄炎を処置するための組成物および方法 |
| WO2014196658A1 (ja) * | 2013-06-06 | 2014-12-11 | 学校法人慶應義塾 | NMO-IgGに拮抗する抗アクアポリン４抗体 |
| WO2015035342A2 (en) | 2013-09-08 | 2015-03-12 | Oligasis Llc | Factor viii zwitterionic polymer conjugates |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| WO2016033509A1 (en) * | 2014-08-29 | 2016-03-03 | The Regents Of The University Of Colorado, A Body Corporate | Aquaporin-4 antibodies and uses thereof for the treatment of neuromyelitis optica |
| KR20210013299A (ko) | 2014-10-17 | 2021-02-03 | 코디악 사이언시스 인코포레이티드 | 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트 |
| EP3072513A1 (en) * | 2015-03-26 | 2016-09-28 | Medday | Biotin for treating Amyotrophic lateral sclerosis |
| AU2016304794B2 (en) | 2015-08-07 | 2021-07-15 | ALX Oncology Inc. | Constructs having a SIRP-alpha domain or variant thereof |
| KR101715127B1 (ko) * | 2015-10-30 | 2017-03-15 | 한국과학기술연구원 | 시신경 척수염 예방 또는 치료용 피리미딘 카복실레이트 유도체 |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| CN116769024A (zh) | 2016-06-14 | 2023-09-19 | 瑞泽恩制药公司 | 抗c5抗体及其用途 |
| WO2018039602A1 (en) * | 2016-08-26 | 2018-03-01 | Wisconsin Alumni Research Foundation | Neuromodulation to modulate glymphatic clearance |
| CA3059938A1 (en) | 2017-04-14 | 2018-10-18 | Kodiak Sciences Inc. | Complement factor d antagonist antibodies and conjugates thereof |
| MX2020002241A (es) | 2017-08-28 | 2020-09-03 | Angiex Inc | Anticuerpos anti-tm4sf y métodos de uso de los mismos. |
| CA3274059A1 (en) | 2017-12-13 | 2026-03-02 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibody combinations and uses thereof |
| EP3758737A4 (en) | 2018-03-02 | 2022-10-12 | Kodiak Sciences Inc. | IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF |
| BR112021004553A2 (pt) | 2018-09-17 | 2021-06-08 | Abcuro, Inc. | anticorpos anti-klrg1 |
| MX2021010254A (es) | 2019-02-27 | 2021-09-21 | Angiex Inc | Conjugados de anticuerpo-farmaco que comprenden anticuerpos anti-tm4sf1 y metodos de uso de los mismos. |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| EP4536290A1 (en) | 2022-06-08 | 2025-04-16 | Angiex, Inc. | Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| JPH049249A (ja) | 1990-04-27 | 1992-01-14 | Kusuda:Kk | 塗型剤吹き付け機 |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| US6569431B2 (en) * | 2000-10-17 | 2003-05-27 | The Regents Of The University Of California | Recombinant antibody fragments as autoantibody antagonists |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US20090042291A1 (en) | 2002-03-01 | 2009-02-12 | Xencor, Inc. | Optimized Fc variants |
| US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| US7285269B2 (en) * | 2002-12-02 | 2007-10-23 | Amgen Fremont, Inc. | Antibodies directed to tumor necrosis factor |
| US7608260B2 (en) | 2003-01-06 | 2009-10-27 | Medimmune, Llc | Stabilized immunoglobulins |
| CA2512729C (en) | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| CA2512974A1 (en) * | 2003-01-13 | 2004-07-29 | Macrogenics, Inc. | Soluble fc.gamma.r fusion proteins and methods of use thereof |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US20070275460A1 (en) | 2003-03-03 | 2007-11-29 | Xencor.Inc. | Fc Variants With Optimized Fc Receptor Binding Properties |
| AU2004266159A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
| US20060134105A1 (en) | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
| GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| US7101679B2 (en) | 2003-11-25 | 2006-09-05 | Mayo Foundation For Medical Education And Research | Marker for neuromyelitis optica |
| EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| EP1737890A2 (en) | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| EP1778726A4 (en) | 2004-08-16 | 2009-03-18 | Medimmune Inc | INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY |
| AU2005285347A1 (en) | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
| WO2006036834A2 (en) | 2004-09-24 | 2006-04-06 | Amgen Inc. | MODIFIED Fc MOLECULES |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| TWI306862B (en) | 2005-01-03 | 2009-03-01 | Hoffmann La Roche | Antibodies against il-13 receptor alpha 1 and uses thereof |
| GT200600065A (es) | 2005-02-14 | 2006-10-02 | Anticuerpos para interleucina-17f y otros antagonistas de la señalizacion de il-17f y sus usos | |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| KR101213894B1 (ko) | 2005-03-02 | 2012-12-20 | 바이오겐 아이덱 엠에이 인코포레이티드 | Ｔｈ2 매개성 병태를 치료하기 위한 ｋｉｍ-1 항체 |
| US20080221120A1 (en) | 2005-03-23 | 2008-09-11 | Alan Verkman | Modulation of Aquaporin in Modulation of Angiogenesis and Cell Migration |
| ATE456574T1 (de) | 2005-09-09 | 2010-02-15 | Hydrogene Lund Ab | Isoliertes aquaporin in seiner geschlossenen konformation |
| WO2007041635A2 (en) | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
| KR20080073293A (ko) | 2005-10-14 | 2008-08-08 | 메디뮨 엘엘씨 | 항체 라이브러리의 세포 디스플레이 |
| US20100112080A1 (en) | 2005-12-13 | 2010-05-06 | Mark Phillip Hogarth | MULTIMERIC Fc RECEPTOR POLYPEPTIDES INCLUDING A MODIFIED Fc DOMAIN |
| CA2638811A1 (en) | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
| JP4273235B2 (ja) | 2006-06-01 | 2009-06-03 | 国立大学法人 新潟大学 | アクアポリン４阻害薬 |
| US20080112961A1 (en) | 2006-10-09 | 2008-05-15 | Macrogenics, Inc. | Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same |
| US8652466B2 (en) | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
| WO2008114011A2 (en) | 2007-03-19 | 2008-09-25 | Medimmune Limited | Fc polypeptide variants obtained by ribosome display methodology |
| US20110077383A1 (en) | 2007-07-03 | 2011-03-31 | Medimmune, Llc | Hinge domain engineering |
| US8889102B2 (en) | 2007-09-20 | 2014-11-18 | Mayo Foundation For Medical Education And Research | Neuromyelitis optica autoantibodies as a marker for neoplasia |
| JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| CL2008003449A1 (es) * | 2007-11-21 | 2010-02-19 | Imclone Llc | Anticuerpo o fragmentos del mismo contra el receptor de proteína estimulante de macrófagos/ron; composición farmacéutica que lo comprende; uso para inhibir angiogénesis, crecimiento tumoral, proliferación, migración e invasión de células tumorales, activación de ron o fosforilación de mapk y/o akt; y uso para tratar cáncer. |
| US8227577B2 (en) * | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| CA2726087A1 (en) | 2008-06-03 | 2009-12-10 | Tariq Ghayur | Dual variable domain immunoglobulins and uses thereof |
| US9891219B2 (en) | 2008-10-10 | 2018-02-13 | Mayo Foundation For Medical Education And Research | Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive |
| GB0819634D0 (en) | 2008-10-25 | 2008-12-03 | Isis Innovation | Autoimmune disorders |
| JP2012515556A (ja) | 2009-01-23 | 2012-07-12 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法 |
| JP5717624B2 (ja) | 2009-03-19 | 2015-05-13 | 中外製薬株式会社 | 抗体定常領域改変体 |
| EP2826789A1 (en) | 2009-03-19 | 2015-01-21 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| ES2829423T3 (es) | 2009-04-20 | 2021-05-31 | Kyowa Kirin Co Ltd | Anticuerpo anti-CD40 que contiene IgG2 que presenta tres mutaciones de aminoácido introducidas en el mismo |
| CN102549016B (zh) | 2009-06-30 | 2015-05-06 | 研究发展基金会 | 免疫球蛋白fc多肽 |
| US8961967B2 (en) | 2009-11-30 | 2015-02-24 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
| WO2011108714A1 (ja) | 2010-03-04 | 2011-09-09 | 中外製薬株式会社 | 抗体定常領域改変体 |
| EP2544706B1 (en) | 2010-03-10 | 2015-06-17 | The University Of Melbourne | Modulating aquaporins with relaxin |
| JP2013528357A (ja) | 2010-03-29 | 2013-07-11 | ザイムワークス，インコーポレイテッド | 強化又は抑制されたエフェクター機能を有する抗体 |
| ES2692268T5 (en) | 2011-03-29 | 2025-02-26 | Roche Glycart Ag | Antibody fc variants |
| JP6152090B2 (ja) | 2011-04-21 | 2017-06-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ | 視神経脊髄炎を処置するための組成物および方法 |
| WO2013177116A1 (en) | 2012-05-21 | 2013-11-28 | The Regents Of The University Of California | Enzymatic modification of anti-aqp4 autoantibody for modulating neuromyelitis optica |
-
2012
- 2012-04-23 JP JP2014506618A patent/JP6152090B2/ja not_active Expired - Fee Related
- 2012-04-23 KR KR20137030627A patent/KR20140059168A/ko not_active Abandoned
- 2012-04-23 US US14/113,061 patent/US10654916B2/en active Active
- 2012-04-23 AU AU2012245205A patent/AU2012245205B2/en not_active Expired - Fee Related
- 2012-04-23 CA CA2833785A patent/CA2833785C/en active Active
- 2012-04-23 EP EP12774049.6A patent/EP2699256B1/en not_active Not-in-force
- 2012-04-23 WO PCT/US2012/034662 patent/WO2012145746A1/en not_active Ceased
- 2012-04-23 CN CN201280030353.5A patent/CN103702682A/zh active Pending
-
2020
- 2020-05-18 US US16/877,103 patent/US11390667B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014514324A5 (https=) | ||
| AU2022221560B2 (en) | TREM2 antigen binding proteins and uses thereof | |
| CN111566215B (zh) | 治疗g蛋白偶联受体介导的病症的组合物和方法 | |
| US11999779B2 (en) | Anti-complement factor C1q Fab fragments and uses thereof | |
| JP2019527678A5 (https=) | ||
| JP2018111728A (ja) | 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法 | |
| JP2017057234A (ja) | 溶血性疾患の処置方法 | |
| IL242088B1 (en) | Anti-transferrin receptor antibodies and methods of use | |
| TW201605473A (zh) | 用於治療骨髓性白血病的表觀遺傳因子與靶向ｃｄ３３及ｃｄ３之雙特異性化合物的組合 | |
| CN105749276A (zh) | Cd37抗体在cll血液样品中的优良效力 | |
| Yu et al. | Monovalent Fc receptor blockade by an anti–Fcγ receptor/albumin fusion protein ameliorates murine ITP with abrogated toxicity | |
| JP7257967B2 (ja) | 抗ｐｄ１抗体試薬に関する方法および組成物 | |
| EP4200324A1 (en) | Multi-paratopic anti-pd-1 antibodies and uses thereof | |
| CA3084602A1 (fr) | Variants avec fragment fc ayant une affinite augmentee pour fcrn et une affinite augmentee pour au moins un recepteur du fragment fc | |
| CA3152489A1 (en) | Methods and compositions for treating diabetic retinopathy | |
| US12146001B2 (en) | Treatment of allergic diseases with chimeric protein | |
| HK1248534A1 (zh) | 周围神经的igg刺激髓鞘再生 | |
| WO2011013470A1 (ja) | 自己抗体産生阻害剤 | |
| IN2014CN04615A (https=) | ||
| CN116249716A (zh) | Mic抗体和结合剂及其使用方法 | |
| WO2012016162A3 (en) | Compositions, methods and kits for modeling, diagnosing, and treating complement disorders | |
| RU2017129335A (ru) | Блокаторы рецептора гормона роста при профилактике заболеваний и лечении | |
| KR102959210B1 (ko) | 레트 증후군의 치료를 위한 세마포린-4d 결합 분자의 용도 | |
| HK40083120A (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| CA3006092C (en) | Anti-complement factor c1q fab fragments and uses thereof |